title: Subsequent entry biologics/biosimilars: a viewpoint from Canada.
abstract: We have reviewed the issues surrounding the advent of biosimilars in the rheumatoid arthritis biologic field. Our proposals emphasize the need to focus primarily on patient safety and to assess the outcomes of therapy both in the short and longer term.
authors.affiliation: 562 Heritage Medical Centre, University of Alberta, Edmonton, AB T6G2S2, Canada. as.russell@ualberta.ca
authors.forename: Anthony S
authors.initials: AS
authors.lastname: Russell
authors.forename: Vandana
authors.initials: V
authors.lastname: Ahluwalla
authors.forename: Cheryl
authors.initials: C
authors.lastname: Barnabe
authors.forename: Shahin
authors.initials: S
authors.lastname: Jamal
authors.forename: Robert C
authors.initials: RC
authors.lastname: Offer
authors.forename: Wojciech P
authors.initials: WP
authors.lastname: Olszynski
authors.forename: Kam
authors.initials: K
authors.lastname: Shojania
authors.forename: Boulos
authors.initials: B
authors.lastname: Haraoui
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001691:Biological Therapy / Q000379:methods*; D059451:Biosimilar Pharmaceuticals / Q000627:therapeutic use*; D002170:Canada; D002626:Chemistry, Pharmaceutical / Q000379:methods; D004247:DNA / Q000378:metabolism; D016527:Drug Costs; D004345:Drug Industry / Q000639:trends; D006801:Humans; D000069285:Infliximab; D061214:Patient Safety; D011995:Recombination, Genetic; D012219:Rheumatology / Q000639:trends; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D059451:Biosimilar Pharmaceuticals; D004247:DNA; C529000:golimumab; D000069285:Infliximab